<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767663</url>
  </required_header>
  <id_info>
    <org_study_id>P3</org_study_id>
    <nct_id>NCT00767663</nct_id>
  </id_info>
  <brief_title>Persantin Preceding Elective PCI</brief_title>
  <acronym>P3</acronym>
  <official_title>Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will investigate whether a short pretreatment (3-7 days) with
      dipyridamole 200mg twice daily will protect patients against myocardial injury sustained
      during an elective dotter operation of the coronary arteries (PCI).

      The investigators hypothesize that dipyridamole can reduce myocardial injury sustained during
      elective PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      In elective PCI (percutaneous coronary intervention) up to 40% of the patients show an
      asymptomatic rise in myonecrosis marker troponin-I. This release of troponin-I has been found
      to represent irreversible myocardial injury and has been related to an increased risk of
      restenosis and even long-term mortality. Dipyridamole has been proven to induce protection
      against ischemia reperfusion injury and to reduce risk of cardiovascular death or event in
      secondary prevention after TIA or CVA.

      Objective:

      To test the hypothesis that dipyridamole improves tolerance to ischemia reperfusion injury in
      patients undergoing elective PCI.

      Study design:

      Double-blind placebo controlled intervention study

      Study population:

      Patients undergoing elective PCI

      Intervention:

      pretreatment with dipyridamole (Persantin Retard) 2dd 200mg or placebo.

      Main study parameters:

      Periprocedural troponin-I release measured 8 hours after PCI.

      Bioequivalence study:

      before the start of th clinical trial we will perform a bioequivalent study to test whether
      our study medication (blinded by recapsuling) equals original dipyridamole capsules. 6
      Healthy volunteers in a cross-over randomised design will take original dipyridamole 200 mg
      SR and recapsuled dipyridamole 200mg SR (prepared by the department of pharmacy of the
      RUNMC). Plasma dipyridamole concentration will be measured frequently and at baseline and 1
      and 3 hours after administration of dipyridamole nucleoside transport inhibitions of
      erythrocytes will be measured, to assess drug activity.

      The clinical trial will only be initialized after conformation of bioequivalence of the study
      medication to the original dipyridamole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac troponin-I</measure>
    <time_frame>before and 8 hours after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of pretreatment with dipyridamole 2x200mg on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9)</measure>
    <time_frame>3 days treatment minimal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of PCI on biomarkers reflecting vascular inflammation (hs-CRP, PLA2, PTX3, IL-6, adiponectin, MCP-1, MMP-9)</measure>
    <time_frame>before and 8 hours after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Percutaneous Transluminal Coronary Angioplasty</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dipyridamole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dipyridamole</intervention_name>
    <description>dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment</description>
    <arm_group_label>1</arm_group_label>
    <other_name>persantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo twice daily, minimal three days pretreatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients accepted for elective single, native vessel (left anterior descending, right
             coronary artery or ramus circumflexus (LAD, RCA or RCX)) PCI in the RUNMC

          -  Troponin-I &lt; 0,20 mmol/L at screening

          -  Signed Informed consent

        Exclusion Criteria:

          -  unstable angina

          -  recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion

          -  3-Vessel disease as seen on coronary angiogram

          -  Stenotic lesion in main stem as seen on coronary angiogram

          -  CABG in medical history

          -  asthma (recurrent episodes of dyspnoea and wheezing, or usage of prescribed inhalation
             medication: i.e. corticosteroids or B2-agonists)

          -  Treatment with insulin

          -  Use of prescribed oral anticoagulants (coumarin derivates)

          -  Use of oral corticosteroids

          -  Use of sulfonylurea derivates (glibenclamide, tolbutamide, gliclazide, glimepiride)

          -  Use of heparin or low molecular weight heparin

          -  Use of metformin

          -  Use of dipyridamole

          -  Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAID's)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RUNMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Kleiman NS. Measuring troponin elevation after percutaneous coronary intervention: ready for prime time? J Am Coll Cardiol. 2006 Nov 7;48(9):1771-3. Epub 2006 Oct 17.</citation>
    <PMID>17084248</PMID>
  </reference>
  <reference>
    <citation>ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May 20;367(9523):1665-73. Erratum in: Lancet. 2007 Jan 27;369(9558):274.</citation>
    <PMID>16714187</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>G. Rongen</investigator_full_name>
    <investigator_title>G. Rongen MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

